Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270".

Despoina Koulenti,Andrew Song,Jeffrey Lipman,Elena Xu,Sotirios Tsiodras,Drosos E Karageorgopoulos,Apostolos Armaganidis,Isaac Yin Sum Mok

doi:10.3390/microorganisms7100386

Abstract

On 18 August 2019, an article was published in Microorganisms presenting novel, approved anti-Gram-positive antibiotics. On 19 August 2019, the U.S. Food and Drug Administration announced the approval of lefamulin, a representative of a new class of antibiotics, the pleuromutilins, for the treatment of adult community-acquired bacterial pneumonia. We present a brief description of lefamulin.

Highlights

On 18 August 2019, an article was published in Microorganisms presenting novel, approved anti-Gram-positive antibiotics [1]
Lefamulin, developed by Nabriva Therapeutics, is a semi-synthetic pleuromutilin mainly studied for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin-structure infections (ABSSSIs) [3]
An in vitro study that assessed the antimicrobial activity of lefamulin against common pathogens causing CABP demonstrated lefamulin to have the lowest minimum inhibitory concentration (MIC) against penicillin non-susceptible and macrolide-resistant Streptococcus pneumoniae among its comparators

Summary

Introduction

On 18 August 2019, an article was published in Microorganisms presenting novel, approved anti-Gram-positive antibiotics [1]. An in vitro study that assessed the antimicrobial activity of lefamulin against common pathogens causing CABP demonstrated lefamulin to have the lowest minimum inhibitory concentration (MIC) against penicillin non-susceptible and macrolide-resistant Streptococcus pneumoniae among its comparators.

Objectives

Results

Conclusion